{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-114660","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2025-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.228067+00:00","generated_at":"2026-05-16T18:07:24.684267+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Edgewise Therapeutics appoints Christopher Martin to Board of Directors","bullets":["Martin, former CCO of Verona Pharma (acquired by Merck for ~$10B), joins as Class I director.","Appointment effective November 19, 2025; term expires at 2028 annual meeting.","Receives $40k annual cash retainer and ~$700k stock option grant (monthly vest over 3 years).","Board cites Martin's commercial launch expertise as critical for Becker MD launch and CV Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-114660","json":"https://secwatch.observer/filing/0001104659-25-114660.json","markdown":"https://secwatch.observer/filing/0001104659-25-114660.md","text":"https://secwatch.observer/filing/0001104659-25-114660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/0001104659-25-114660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465925114660/tm2531112d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:07:24.684267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}